This article confusingly talks about atomoxetine in several places, but atomoxetine is very different than Adderall, in particular, because it's not a stimulant.
Given the papers clearly state that some of these risks/issues are only appreciable for the amphetamine variants (and some only appreciable for the non-amphetamine drugs), this is, imho, a disservice.
There is a single anecdote about atomoxetine. The quote has nothing to do with the drug's action. The point of the anecdote is the researchers' attitude toward the behaviour of young children, in the context of debating their approach to judging side-effects. That is certainly relevant context: the paper in question is also looking at side-effects for amphetamine variants. Strange approaches to behaviour classification likely apply across all the trials involved.
Your original comment was that this is confusing. I think it's very clear. I am not left with the impression that results for atomoxetine are being conflated with results for amphetamine variants.